238 related articles for article (PubMed ID: 25618421)
21. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).
Mendes RE; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):93-7. PubMed ID: 21851873
[TBL] [Abstract][Full Text] [Related]
22. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
[TBL] [Abstract][Full Text] [Related]
23. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
Mendes RE; Sader HS; Flamm RK; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
[TBL] [Abstract][Full Text] [Related]
24. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
26. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
27. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
[TBL] [Abstract][Full Text] [Related]
29. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
30. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
32. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 May; 43(5):465-9. PubMed ID: 24636430
[TBL] [Abstract][Full Text] [Related]
33. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.
Farrell DJ; Mendes RE; Rhomberg PR; Jones RN
Antimicrob Agents Chemother; 2014 Sep; 58(9):5547-51. PubMed ID: 25022579
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
Hope R; Chaudhry A; Adkin R; Livermore DM
Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
[TBL] [Abstract][Full Text] [Related]
35. Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.
Huang DB; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):329-334. PubMed ID: 29306582
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
37. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
38. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
Mendes RE; Sader HS; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2012 Jul; 56(7):3999-4004. PubMed ID: 22508304
[TBL] [Abstract][Full Text] [Related]
39. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007).
Sader HS; Moet G; Jones RN
J Chemother; 2009 Nov; 21(5):500-6. PubMed ID: 19933040
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
Karlowsky JA; Walkty AJ; Baxter MR; Arhin FF; Moeck G; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):349-356. PubMed ID: 28159446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]